Bloomberg Turnaround: How a CEO Doubled His Company's Share Price

The transcript discusses Zeneca's research facility in Sweden, emphasizing open communication among scientists to foster breakthroughs. It highlights AstraZeneca's new headquarters in Cambridge and the challenges faced due to expiring patents. In 2012, Pascal Soriot was appointed CEO to address these issues, leading to a strategic shift from cost-cutting to focusing on science and medicine development, resulting in a doubled share price. The turnaround was supported by IBM services.

What is the purpose of removing walls at AstraZeneca's research facility in Sweden?

• To improve building aesthetics

• To increase office space

• To promote conversation among scientists

• To reduce construction costs

What major financial challenge was AstraZeneca facing in 2011?

• A decline in stock prices

• A loss of $17 billion in sales due to expiring patents

• A shortage of research funding

• An increase in operational costs

Who was appointed as AstraZeneca's chief executive in 2012?

• Andrew Witty

• Emma Walmsley

• John Smith

• Pascal Soriot

What was the primary focus of AstraZeneca's strategy under Pascal Soriot's leadership?

• Cost-cutting and reorganization

• Share buybacks

• Focusing on science and developing medicines

• Expanding into new markets

What was the result of AstraZeneca's strategic shift under Pascal Soriot?

• A reduction in workforce

• A decrease in research funding

• A decline in market share

• A doubled share price